T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in Children
Phase 1 and Phase 2/3 trials (NCT04816643) demonstrated that the mRNA-based coronavirus disease 2019 (COVID-19) vaccine BNT162b2 is tolerable and efficacious in (5-11-year-olds) following two 10 µg doses 21 days apart, and a third 10 µg dose after 6 months. Here, we show that vaccination induces neutralizing antibodies and T-cell immunogenicity in 10-11-year-old participants.
Authors
- Özlem Türeci (ORCID: https://orcid.org/0000-0002-0623-1497)
- Nicholas Kitchin (ORCID: https://orcid.org/0000-0002-1808-3380)
- Stephanie Renken
- Andrew Finlayson (ORCID: https://orcid.org/0000-0003-0793-7878)
- Kena A. Swanson (ORCID: https://orcid.org/0000-0002-3389-8414)
- Stephen Lockhart (ORCID: https://orcid.org/0000-0002-0805-2193)
- Kathrin U. Jansen (ORCID: https://orcid.org/0000-0001-5354-4202)
- Rolf Hilker (ORCID: https://orcid.org/0000-0002-8576-7731)
- Charu Sabharwal (ORCID: https://orcid.org/0000-0002-1875-0577)
- Isabel Vogler (ORCID: https://orcid.org/0000-0001-9757-9618)
- Alejandra Gurtman (ORCID: https://orcid.org/0000-0003-3469-1201)
- Uğur Şahin (ORCID: https://orcid.org/0000-0003-0363-1564)
- William C. Gruber (ORCID: https://orcid.org/0000-0002-6518-4547)
- Bonny Gaby Lui (ORCID: https://orcid.org/0000-0002-8260-5075)
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Johannes Gutenberg University Mainz (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Helmholtz Institute Mainz (DE)
- BioNTech (Germany) (DE)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1093/ofid/ofaf699
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00